Merus is an immuno-oncology company at the clinical stage that is developing original full-length human bispecific antibody therapeutics, which are known as Biclonics®. Biclonics® are based on the full-length IgG format, and they are produced using standard industry procedures. In preclinical studies, they have been found to exhibit similar characteristics to traditional monoclonal antibodies, such as extended half-life and minimal immunogenicity.